Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR
Range Of New Modalities Put To Test
Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.
